Understanding Immunosuppressive Therapy In Itp
Exploring Immunosuppressive Therapy In Itp reveals several interesting facts. Ivy Altomare, MD; Keith R. McCrae, MD; and Terry Gernsheimer, MD, review the potential for treating adult idiopathic ...
Key Takeaways about Immunosuppressive Therapy In Itp
- Dr Townsley talks to ecancertv at ASH 2015 about adding eltrombopag to standard
- Ivy P. Altomare, MD, discusses some of the challenges of treating patients with immune
- Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, ...
- Nichola Cooper, MD, FRCP, FRCPath, Imperial College London, London, UK, discusses two novel
- James B. Bussel, MD, describes the second-line
Detailed Analysis of Immunosuppressive Therapy In Itp
James B. Bussel, MD, explains the effects of long-term James B. Bussel, MD, discusses the second-line and later-line James B. Bussel, MD, reviews the duration for first-line
Ivy Altomare, MD; Keith R. McCrae, MD; and Terry Gernsheimer, MD, review clinical considerations for initiating
Stay tuned for more updates related to Immunosuppressive Therapy In Itp.
